Species Used for Drug Testing Reveal Different Inhibition Susceptibility for 17beta-Hydroxysteroid Dehydrogenase Type 1

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Möller, Gabriele ^a   Husen, Bettina ^b,g   Kowalik, Dorota ^a   Hirvelä, Leena ^c   Plewczynski, Dariusz ^d   Rychlewski, Leszek ^e   Messinger, Josef ^b   Thole, Hubert ^b   Adamski, Jerzy ^a,f  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b Solvay Pharmaceuticals GmbH   (Germany)

^c Hormos Medical Ltd   (Finland)

^d UNIVERSITY OF WARSAW   (Poland)

^e BioInfoBank Institute   (Poland)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTRONE; OXIDOREDUCTASE INHIBITOR; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 1; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 1 INHIBITOR; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 2; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 4; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 5; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 7; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; IC 50; IN VITRO STUDY; MARMOSET; MOLECULAR DOCKING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; RAT; SPECIES DIFFERENCE; SWINE;

ANIMALS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; ESTRADIOL DEHYDROGENASES; HUMANS; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY;

ANIMALIA; MARMOSETS; RATTUS; RODENTIA; SUIDAE;

EID: 77956199036     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010969     Document Type: Article

References (71)

1. Hardy LW, Peet NP (2004) The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets. Drug Discov Today 9: 117-126.
2. Plewczynski D, Rychlewski L (2008) Meta-basic estimates the size of druggable human genome. J Mol Model 15: 484-489.
3. Vihko P, Harkonen P, Soronen P, Torn S, Herrala A, et al. (2004) 17beta-Hydroxysteroid dehydrogenases-their role in pathophysiology. Mol Cell Endocrinol 215: 83-88.
4. Luu-The V (2001) Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 76: 143-151.
5. Lukacik P, Kavanagh KL, Oppermann U (2006) Structure and function of human 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 248: 61-71.
6. Möller G, Adamski J (2009) Integrated view on 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 301: 7-19.
7. Prehn C, Möller G, Adamski J (2009) Recent advances in 17beta-hydroxysteroid dehydrogenases. J Steroid Biochem Mol Biol 114: 72-77.
8. Persson B, Kallberg Y, Bray JE, Bruford E, Dellaporta SL, et al. (2009) The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. Chem Biol Interact 178: 94-98.
9. Jin Y, Penning TM (2007) Aldo-Keto Reductases and Bioactivation/Detoxication. Annu Rev Pharmacol Toxicol 47: 263-292.
10. Oduwole OO, Li Y, Isomaa VV, Mantyniemi A, Pulkka AE, et al. (2004) 17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res 64: 7604-7609.
11. Gunnarsson C, Hellqvist E, Stal O (2005) 17beta-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer. Br J Cancer 92: 547-552.
12. Jansson AK, Gunnarsson C, Cohen M, Sivik T, Stal O (2006) 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer. Cancer Res 66: 11471-11477.
13. Gunnarsson C, Jerevall PL, Hammar K, Olsson B, Nordenskjold B, et al. (2008) Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer. Breast Cancer Res Treat 108: 35-41.
14. Rasiah KK, Gardiner-Garden M, Padilla EJ, Möller G, Kench JG, et al. (2009) HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer. Mol Cell Endocrinol 301: 89-96.
15. Poirier D (2003) Inhibitors of 17beta-hydroxysteroid dehydrogenases. Curr Med Chem 10: 453-477.
16. Lawrence HR, Vicker N, Allan GM, Smith A, Mahon MF, et al. (2005) Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors. J Med Chem 48: 2759-2762.
17. Tchedam Ngatcha B, Luu-The V, Labrie F, Poirier D (2005) Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship. J Med Chem 48: 5257-5268.
18. Allan GM, Lawrence HR, Cornet J, Bubert C, Fischer DS, et al. (2006) Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem 49: 1325-1345.
19. Vicker N, Lawrence HR, Allan GM, Bubert C, Smith A, et al. (2006) Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Chem Med Chem 1: 464-481.
20. Frotscher M, Ziegler E, Marchais-Oberwinkler S, Kruchten P, Neugebauer A, et al. (2008) Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. J Med Chem 51: 2158-2169.
21. Brosic P, Risner TL, Gobec S (2008) Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Curr Med Chem 15: 137-150.
22. Allan GM, Vicker N, Lawrence HR, Tutill HJ, Day JM, et al. (2008) Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design. Bioorg Med Chem 16: 4438-4456.
23. Day JM, Tutill HJ, Purohit A, Reed MJ (2008) Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr Relat Cancer 15: 665-692.
24. Messinger J, Husen B, Koskimies P, Hirvelä L, Kallio L, et al. (2008) Estrone C15 derivatives-a new class of 17 beta hydroxysteroid dehydrogenase 1 inhbitors. Molecular and Cellular Endocrinology 301: 216-224.
25. Deluca D, Möller G, Rosinus A, Elger W, Hillisch A, et al. (2006) Inhibitory effects of fluorine-substituted estrogens on the activity of 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 248: 218-224.
26. Vihko P, Herrala A, Harkonen P, Isomaa V, Kaija H, et al. (2006) Control of cell proliferation by steroids: The role of 17HSDs. Mol Cell Endocrinol 248: 141-148.
27. Luu-The V, Belanger A, Labrie F (2008) Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 22: 207-221.
28. Preslock JP (1980) A review of in vitro testicular steroidogenesis in rodents, monkeys and humans. J Steroid Biochem 13: 965-975.
29. Peltoketo H, Luu-The V, Simard J, Adamski J (1999) 17beta-hydroxysteroid dehydrogenase (HSD)/17-keto steroid reductase (KSR) family: nomenclature and main characteristics of the 17HSD/KSR enzymes. Journal of Molecular Endocrinology 23: 1-11.
30. Peltoketo H, Nokelainen P, Piao YS, Vihko R, Vihko P (1999) Two 17beta-hydroxysteroid dehydrogenases (17HSDs) of estradiol biosynthesis: 17HSD type 1 and type 7. J Steroid Biochem Mol Biol 69: 431-439.
31. Kruchten P, Werth R, Marchais-Oberwinkler S, Bey E, Ziegler E, et al. (2009) Development of biological assays for the identification of selective inhibitors of estradiol formation from estrone in rat liver preparations. C R Chim 12: 1110-1116.
32. Geissler W, Davis D, Wu L, Bradshaw K, Patel S, et al. (1994) Male pseudohermaphroditism caused by mutations of testicular 17ß-hydroxysteroid dehydrogenase 3. Nature Genetics 7: 34-39.
33. Lukacik P, Keller B, Bunkoczi G, Kavanagh KL, Lee WH, et al. (2007) Structural and biochemical characterization of human orphan DHRS10 reveals a novel cytosolic enzyme with steroid dehydrogenase activity. Biochem J 402: 419-427.
34. Day JM, Foster PA, Tutill HJ, Parsons MF, Newman SP, et al. (2008) 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int J Cancer 122: 1931-1940.
35. Vicker N, Lawrence HRR, Allan GM, Bubert C, Fischer DSM, et al. (2004) 17beta-hydroxysteroid dehydrogenase inhibitors. Patent WO/2004/085457.
36. Messinger J, Schoen U, Thole H, Husen B, Koskimies P, et al. (2008) Therapeutically active triazoles and their use. Patent US 2008/0146531 A1.
37. Huang YW, Pineau I, Chang HJ, Azzi A, Bellemare V, et al. (2001) Critical residues for the specificity of cofactors and substrates in human estrogenic 17beta-hydroxysteroid dehydrogenase 1: variants designed from the three-dimensional structure of the enzyme. Mol Endocrinol 15: 2010-2020.
38. Penning TM (2003) Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action. Hum Reprod Update 9: 193-205.
39. Penning TM, Jin Y, Rizner TL, Bauman DR (2008) Pre-receptor regulation of the androgen receptor. Mol Cell Endocrinol 281: 1-8.
40. Mindnich R, Moller G, Adamski J (2004) The role of 17 beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 218: 7-20.
41. Foster PA, Reed MJ, Purohit A (2008) Recent developments of steroid sulfatase inhibitors as anti-cancer agents. Anticancer Agents Med Chem 8: 732-738.
42. Purohit A, Chander SK, Woo LW, Parsons MF, Jhalli R, et al. (2008) Inhibition of steroid sulphatase activity via the percutaneous route: a new option for breast cancer therapy. Anticancer Res 28: 1517-1523.
43. Brodie A, Sabnis G, Jelovac D (2006) Aromatase and breast cancer. J Steroid Biochem Mol Biol 102: 97-102.
44. Suzuki T, Miki Y, Moriya T, Akahira J, Ishida T, et al. (2007) 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. Int J Cancer 120: 285-291.
45. Schuster D, Laggner C, Steindl TM, Palusczak A, Hartmann RW, et al. (2006) Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors. J Chem Inf Model 46: 1301-1311.
46. Woo LW, Bubert C, Sutcliffe OB, Smith A, Chander SK, et al. (2007) Dual aromatase-steroid sulfatase inhibitors. J Med Chem 50: 3540-3560.
47. Poirier D (2009) Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases. Anticancer Agents Med Chem 9: 642-660.
48. Kruchten P, Werth R, Bey E, Oster A, Marchais-Oberwinkler S, et al. (2009) Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells. J Steroid Biochem Mol Biol 114: 200-206.
49. Kruchten P, Werth R, Marchais-Oberwinkler S, Frotscher M, Hartmann RW (2009) Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents. Mol Cell Endocrinol 301: 154-157.
50. Tremblay MR, Boivin RP, Luu-The V, Poirier D (2005) Inhibitors of type 1 17beta-hydroxysteroid dehydrogenase with reduced estrogenic activity: modifications of the positions 3 and 6 of estradiol. J Enzyme Inhib Med Chem 20: 153-163.
51. Poirier D, Chang HJ, Azzi A, Boivin RP, Lin SX (2006) Estrone and estradiol C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase. Mol Cell Endocrinol 248: 236-238.
52. Fischer DS, Allan GM, Bubert C, Vicker N, Smith A, et al. (2005) E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem 48: 5749-5770.
53. Schwarz S, Thieme I, Richter M, Undeutsch B, Henkel H, et al. (1996) Synthesis of estrogen sulfamates: compounds with a novel endocrinological profile. Steroids 61: 710-717.
54. Poirier D, Ciobanu LC, Berube M (2002) A multidetachable sulfamate linker successfully used in a solid-phase strategy to generate libraries of sulfamate and phenol derivatives. Bioorg Med Chem Lett 12: 2833-2838.
55. Bey E, Marchais-Oberwinkler S, Negri M, Kruchten P, Oster A, et al. (2009) New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity. J Med Chem 52: 6724-6743.
56. Qiu W, Campbell RL, Gangloff A, Dupuis P, Boivin RP, et al. (2002) A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity. Faseb J 16: 1829-1831.
57. Berube M, Poirier D (2004) Synthesis of simplified hybrid inhibitors of type 1 17beta-hydroxysteroid dehydrogenase via cross-metathesis and sonogashira coupling Reactions. Org Lett 6: 3127-3130.
58. Brown WM, Metzger LE, Barlow JP, Hunsaker LA, Deck LM, et al. (2003) 17-beta-Hydroxysteroid dehydrogenase type 1: computational design of active site inhibitors targeted to the Rossmann fold. Chem Biol Interact 143-144: 481-491.
59. Gunn D, Akuche C, Baryza J, Blue ML, Brennan C, et al. (2005) 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 2. SAR. Bioorg Med Chem Lett 15: 3053-3057.
60. Marchais-Oberwinkler S, Kruchten P, Frotscher M, Ziegler E, Neugebauer A, et al. (2008) Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics. J Med Chem 51: 4685-4698.
61. Messinger J, Thole H-H, Husen B, Van Steen BJ, Scheider G, et al. (2008) Novel 17beta hydroxysteroid dehydrogenase type I inhibitors. Patent 1685150. WO2004080271A. Patent 1685150 WO2004080271A.
62. Arampatzis S, Kadereit B, Schuster D, Balazs Z, Schweizer RA, et al. (2005) Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol 35: 89-101.
63. Leenders F, Tesdorpf JG, Markus M, Engel T, Seedorf U, et al. (1996) Porcine 80-kDa protein reveals intrinsic 17 beta-hydroxysteroid dehydrogenase, fatty acyl-CoA-hydratase/dehydrogenase, and sterol transfer activities. J Biol Chem 271: 5438-5442.
64. Adamski J (1991) Isolation of vesicles mediating the conversion of 17 beta-estradiol to estrone. Eur J Cell Biol 54: 166-170.
65. Poirot O, O'Toole E, Notredame C (2003) Tcoffee@igs: A web server for computing, evaluating and combining multiple sequence alignments. Nucleic Acids Res 31: 3503-3506.
66. Lin SX, Han Q, Azzi A, Zhu DW, Gongloff A, et al. (1999) 3D-structure of human estrogenic 17beta-HSD1: binding with various steroids. J Steroid Biochem Mol Biol 69: 425-429.
67. Azzi A, Rehse PH, Zhu DW, Campbell RL, Labrie F, et al. (1996) Crystal structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase complexed with 17 beta-estradiol. Nat Struct Biol 3: 665-668.
68. Qiu W, Zhou M, Labrie F, Lin SX (2004) Crystal structures of the multispecific 17beta-hydroxysteroid dehydrogenase type 5: critical androgen regulation in human peripheral tissues. Mol Endocrinol 18: 1798-1807.
69. Koski KM, Haapalainen AM, Hiltunen JK, Glumoff T (2005) Crystal structure of 2-enoyl-CoA hydratase 2 from human peroxisomal multifunctional enzyme type 2. J Mol Biol 345: 1157-1169.
70. Haller F, Moman E, Hartmann RW, Adamski J, Mindnich R (2010) Molecular Framework of Steroid/Retinoid Discrimination in 17beta-Hydroxysteroid Dehydrogenase Type 1 and Photoreceptor-associated Retinol Dehydrogenase. J Mol Biol. in press: doi:10.1016/j.jmb.2010.1004.1002.
71. Koczyk G, Wyrwicz LS, Rychlewski L (2007) LigProf: a simple tool for in silico prediction of ligand-binding sites. J Mol Model 13: 445-455.